Last reviewed · How we verify
Coniel (BENIDIPINE)
At a glance
| Generic name | BENIDIPINE |
|---|---|
| Drug class | benidipine |
| Target | Voltage-dependent T-type calcium channel subunit alpha-1H, Voltage-gated L-type calcium channel |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Benidipine in Hypertensive and/or Chronic Coronary Syndrome Patients
- Cerebral Autoregulation Guiding Blood Pressure Management After Revascularization (PHASE2)
- Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension (PHASE4)
- Benidipine-based Comparison of Angiotensin Receptors, β-blockers, or Thiazide Diuretics in Hypertensive Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Coniel CI brief — competitive landscape report
- Coniel updates RSS · CI watch RSS